17117-12-3

Basic information

• Product Name: 2-Bromo-4-methylpyridine N-oxide
• Synonyms: 2-Bromo-4-methylpyridine N-oxide;2-Bromo-4-picoline 1-oxide;2-BroMo-4-Methylpyridine 1-oxide
• CAS NO: 17117-12-3
• Molecular Formula: C6H6BrNO
• Molecular Weight: 188.02
• Mol File: 17117-12-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 343.321°C at 760 mmHg
• Flash Point: 161.435°C
• Appearance: /
• Density: 1.56
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: 2-Bromo-4-methylpyridine N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-methylpyridine N-oxide(17117-12-3)
• EPA Substance Registry System: 2-Bromo-4-methylpyridine N-oxide(17117-12-3)

Safety Data

• Hazardous Substances Data: 17117-12-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-methylpyridine N-oxide is a chemical compound often used in the field of scientific research. Its molecular formula is C6H6BrNO and it falls under the category of Bromopyridines. It possesses a molar mass of 188.02 g/mol, and appears as a clear light yellow to brown liquid. It's soluble in water and usually kept in a cool, ventilated area far from ignition sources. Due to its potential hazard for the environment, it needs to be handled with care, avoiding release into the environment without proper treatment. It is highly advisable to wear suitable protective equipment while working with this chemical.

InChI:InChI=1/C6H6BrNO/c1-5-2-3-8(9)6(7)4-5/h2-4H,1H3

Upstream product

• 4926-28-7 2-Bromo-4-picoline 

Downstream Products

• 25363-69-3 1-hydroxy-4-methylpyridine-2(1H)-thione 
• 18368-65-5 4-Methyl-pyridthion-(2) 

Relevant articles and documents

Towards Identification of Essential Structural Elements of Organoruthenium(II)-Pyrithionato Complexes for Anticancer Activity

An organoruthenium(II) complex with pyrithione (2-mercaptopyridine N-oxide) 1 a has previously been identified by our group as a compound with promising anticancer potential without cytotoxicity towards non-cancerous cells. To expand the rather limited research on compounds of this type, an array of novel chlorido and 1,3,5-triaza-7-phosphaadamantane (pta) organoruthenium(II) complexes with methyl-substituted pyrithiones has been prepared. After thorough investigation of the aqueous stability of these complexes, their modes of action have been elucidated at the cellular level. Minor structural alterations in the ruthenium-pyrithionato compounds resulted in fine-tuning of their cytotoxicities. The best performing compounds, 1 b and 2 b, with a chlorido or pta ligand bound to ruthenium, respectively, and a methyl group at the 3-position of the pyrithione scaffold, have been further investigated. Both compounds trigger early apoptosis, induce the generation of reactive oxygen species and G1 arrest in A549 cancer cells, and show no strong interaction with DNA. However, only 1 b also inhibits thioredoxin reductase. Wound healing assays and mitochondrial function evaluation have revealed differences between these two compounds at the cellular level.